Sign up to save your podcasts
Or
Share The Future of Genetic Medicine with Zandy Forbes, CEO of MeiraGTx
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Future of Genetic Medicine with Zandy Forbes, CEO of MeiraGTx
What compels a scientist to leave academia for the high-stakes world of finance and then become the CEO of a publicly-traded biotech company?
In this episode of Oxford+, host Susannah de Jager sits down with Zandy Forbes, the CEO and co-founder of MeiraGTx. Zandy shares her fascinating career journey, explaining how her experience as a hedge fund analyst shaped her unique approach to building a resilient, multi-asset genetic medicine company.
They discuss MeiraGTx's pioneering work, from developing a mind-blowing technology that turns the body into a drug manufacturing facility to their successful clinical trials that are changing the lives of patients with inherited blindness, Parkinson’s, and other diseases.
- (00:00) - Welcome to Oxford+
Zandy Forbes: The CEO and co-founder of MeiraGTx, a NASDAQ-listed clinical-stage genetic medicine company. She holds a double first in Natural Sciences from Cambridge University and a PhD in Molecular Genetics from the University of Oxford. Before co-founding MeiraGTx in 2015, she spent over a decade as an analyst and portfolio manager at a healthcare-focused hedge fund.
Connect with Zandy on LinkedIn
Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.
Connect with Susannah on LinkedIn / Subscribe to the Oxford+ Newsletter for exclusive content
Oxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and Oxford North.
Produced and edited by Story Ninety-Four in Oxford.
View all episodes
By Susannah de JagerWhat compels a scientist to leave academia for the high-stakes world of finance and then become the CEO of a publicly-traded biotech company?
In this episode of Oxford+, host Susannah de Jager sits down with Zandy Forbes, the CEO and co-founder of MeiraGTx. Zandy shares her fascinating career journey, explaining how her experience as a hedge fund analyst shaped her unique approach to building a resilient, multi-asset genetic medicine company.
They discuss MeiraGTx's pioneering work, from developing a mind-blowing technology that turns the body into a drug manufacturing facility to their successful clinical trials that are changing the lives of patients with inherited blindness, Parkinson’s, and other diseases.
- (00:00) - Welcome to Oxford+
Zandy Forbes: The CEO and co-founder of MeiraGTx, a NASDAQ-listed clinical-stage genetic medicine company. She holds a double first in Natural Sciences from Cambridge University and a PhD in Molecular Genetics from the University of Oxford. Before co-founding MeiraGTx in 2015, she spent over a decade as an analyst and portfolio manager at a healthcare-focused hedge fund.
Connect with Zandy on LinkedIn
Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.
Connect with Susannah on LinkedIn / Subscribe to the Oxford+ Newsletter for exclusive content
Oxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and Oxford North.
Produced and edited by Story Ninety-Four in Oxford.